Cargando…

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

BACKGROUND: We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700279/ https://www.ncbi.nlm.nih.gov/pubmed/34953520 http://dx.doi.org/10.1016/S1473-3099(21)00751-9

Ejemplares similares

LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
por: Evering, Teresa H, et al.
Publicado: (2021)

Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults
por: Hao, Xiaohua, et al.
Publicado: (2022)

520. Pharmacokinetic and Safety Phase 1 Study and Microneutralization Assay Results with BRII-196/BRII-198, a Novel Antibody Cocktail Active Against a Wide Range of SARS-CoV-2 Variants
por: Margolis, David A, et al.
Publicado: (2021)

Effect of the Timing of Amubarvimab/Romlusevimab (BRII-196/198) Administration on Progression to Severe Disease in Elderly Patients with COVID-19 Infection: A Retrospective Cohort Study
por: Xu, Yonghao, et al.
Publicado: (2023)

1283. Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects
por: Margolis, David A, et al.
Publicado: (2022)

Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study
por: Ma, Haiyan, et al.
Publicado: (2021)

The Ticos : culture and social change in Costa Rica /
por: Biesanz, Mavis Hiltunen
Publicado: (1999)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
por: Berry, Jody D, et al.
Publicado: (2004)

Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
por: Totschnig, David, et al.
Publicado: (2022)

Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab
por: Magnus, Clara Luzia, et al.
Publicado: (2022)

Collectivity in ${}^{\mathrm{196,198}}$Pb isotopes probed in Coulomb-excitation experiments at REX-ISOLDE
por: Pakarinen, J, et al.
Publicado: (2017)

In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys
por: Aweda, Tolulope A., et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

TICO: a tool for postprocessing the predictions of prokaryotic translation initiation sites
por: Tech, M., et al.
Publicado: (2006)

Cinco ensayos cr´ticos de la economía e historia
por: Flores Nava, Fabiola Jesavel

Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking
por: Acquaye‐Seedah, Edith, et al.
Publicado: (2018)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment of Early Mild-to-Moderate COVID-19
por: Gupta, Anil K, et al.
Publicado: (2022)

G196 epitope tag system: a novel monoclonal antibody, G196, recognizes the small, soluble peptide DLVPR with high affinity
por: Tatsumi, Kasumi, et al.
Publicado: (2017)

Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation
por: Seow, Han Cong, et al.
Publicado: (2023)

Mechanisms of Rhinovirus Neutralisation by Antibodies
por: Touabi, Lila, et al.
Publicado: (2021)

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
por: Kreye, Jakob, et al.
Publicado: (2023)

Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS
por: Adachi, Eisuke, et al.
Publicado: (2022)

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
por: Harman, Katie, et al.
Publicado: (2023)

Engineering, Expression in Transgenic Plants and Characterisation of E559, a Rabies Virus-Neutralising Monoclonal Antibody
por: van Dolleweerd, Craig J., et al.
Publicado: (2014)

EE315 Economic Evaluation of Neutralising Monoclonal Antibodies for the Treatment of COVID-19 Positive People in the Community
por: Metry, A, et al.
Publicado: (2022)

Information and communication technologies and quality of life in home confinement: Development and validation of the TICO scale
por: García del Castillo-Rodríguez, José Antonio, et al.
Publicado: (2020)

Factors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial
por: Cho, Jae Young, et al.
Publicado: (2021)

Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody
por: Quijada, Hector, et al.
Publicado: (2021)

Neutralising Antibodies against Ricin Toxin
por: Prigent, Julie, et al.
Publicado: (2011)

Experience of the United Arab Emirates in the use of monoclonal antibody drug sotrovimab in high-risk vaccinated and unvaccinated patients with COVID-19: an observational cohort study
por: Abdalateef, Sumaya, et al.
Publicado: (2023)

Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants
por: Moore, Catherine M., et al.
Publicado: (2021)

Dientes ChiquiTICOS: an analysis of juvenile dentition and dental health in Costa Rican indigenous communities
por: García, Alfredo, et al.
Publicado: (2007)

Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study
por: Murrell, Isa, et al.
Publicado: (2021)

Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B
por: Gray, Elin Solomonovna, et al.
Publicado: (2006)

Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis
por: McConnell, David, et al.
Publicado: (2022)

Neutralising antibodies for Mayaro virus in Pantanal, Brazil
por: Pauvolid-Corrêa, Alex, et al.
Publicado: (2015)

Schmallenberg virus neutralising antibody responses in sheep
por: Jones, Scott, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v6tbmb9a803qn7h39a06lmjt9d